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Introduction and Summary 
 
 
1. Reform in Medical Care System in China 
At the National People’s Congress in 2006, Spring, Prime Wen Jiabao announced that 
the government will conquer a problem of “Expensive doctor’s examination, and 
difficult to see doctor” that troubles the public general with high fees.  
   The state government commissioned 7 institutes, which increased to 8 later, to build 
up policy agenda on 7 subtopics on medical reform started in September 2006: Seven 
institutions were Development Research Center, Peking University, Fudan University, 
World Bank, WHO, Beijing Normal University and Beijing Renmin University.  6 out 
of them claim that the reform needs to introduce competition by extending coverage of 
medical health insurance. Though no agenda were disclosed to the public, some media 
reported that direction of reform is being concluded into two principles: (1) To extend 
coverage of medical insurance. (2) To further introduce market mechanism.  
According to the media report, 6 agenda out of 8 institutions proposed to induce 
competition by building up medical insurances who will be a direct payer of medical 
services( 21th Century Economic Report 2007 July, 19) .    
   Though controversy is still going on, principles above are not finally authorized,  
these principles have following advantages for the pharmaceutical industry in China. 
 (1) To extend coverage of medical insurance: As we will see below, current 
medical insurance covers only less than half of the whole nation. Particularly, coverage 
of medical insurance in the rural area is extremely low, though the new rural 
cooperative medical insurance is spreading its coverage. To build up medical insurance 
that covers whole population will have a substantial impact on the market of medical 
service and pharmaceuticals: (1) the insurance itself has a redistributing function 
between the healthy and the sick as nobody can expect when you got ill. The insurance 
should be compulsory, otherwise we cannot only expect for insurance function to work, 
but will induce “adverse selection problem.” (2) As budget of medical insurance is 
limited to total insurance fee income, thus the insurance has strong incentive to reduce 
medical cost. This incentive is much stronger than payment-by-tax system, thus we can 
expect cost to be saved. Thus, we can expect to reform a notorious “Feeding Hospital by 
Drug (以药养医)” mechanism. (3) For the pharmaceutical industry, it implies that direct 
purchasers of drug are changed from the hospital to the insurance. Pricing principles of 
the insurance would drastically change, demand for drug will be changed. 
(2) To introduce market mechanism in deep. Main issue of controversy on medical 
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reform has been whether to introduce market mechanism more or to strengthen the grip 
of government: Question also becomes whether to subsidize supply side or demand side. 
It seems that the former are getting dominant: to extend coverage of medical insurance 
is the one example. The other claim is to let private capital to run hospitals to induce 
competition. Currently, all hospitals are basically state owned, and all physicians and 
nurses are civil servants in China. This state-owned and-run hospital system presents a 
substantial supply shortage of medical services. If entry of private and foreign capital 
were liberalized in medical service industry, demand for drug will be diversified and 
increased. This will create a new market for drug manufacturers in China.  
 
2.   Feature of pharmaceutical industry  
Before considering case of China, take a look at what is the nature of pharmaceutical 
industry? Nambu[2006] summarizes the features as follows: 
(1) Intervention by the government is deep: Except the United State, the industry 
of all over the world are heavily intervened by the government, e.g. price of products, 
profit ratio of firms etc.. In the most industry, pricing is the most important tool to 
represent firm’s strategy; profit is a result of the strategy. However, in the 
pharmaceutical industry, firms are intervened into these key factors. Even in the United 
State, the government strictly monitors safety and quality at every stage of production, 
sales and clinical trials. Philosophy behind the United States regulation is that strict 
monitoring and control at stages before sales will keeps the cost of safety control at 
lowest, because in case accident happens after sales, cost to recover safety will become 
huge. Furthermore, free market of the products leads to cheapest and the most efficient 
price for the consumer, though equivalent among nation could be ignored, as only richer 
person can enjoy good enough medical care. 
(2) Special nature of demand: Demand for drug have several special features: first, 
physician, who is an agent of patient, consumer of drug, will decide to buy which drug 
and how much. Usually, information asymmetry on drug knowledge is huge between 
physicians and patients, thus agency problem between the two is a serious and 
important issue. Second, medical insurance will pay for patient. There exist another 
agency problem between insurance, physician and patient. Thus it is a very prevalent 
phenomena that physician will prescribe excessively high price drug to increase their 
revenue, not for reduce burden of patient, when the medical system is designed poorly 
to resolve these agency problems. In developing economies, where coverage of social 
security system is limited, physician depends on direct revenue from patient, this 
agency problem become more acute. 
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(3) Supply by private firms: Though government intervention is so deep as we saw, 
supplier, pharmaceutical firms are private owned firms in most economies. It is rare that 
state owned enterprises supply drugs in the market economy, which is contrasting to the 
utility industries such as electricity or water supplies, that are often supplied by public 
owned firms in the market economy. Nature of the industry, variety of products is wide, 
product selection is very quick, requires supplier a quick and flexible supply of products. 
Monopolized SOEs, presumably speaking, cannot meet these demand 
(Nambu[2006:p2]). 
 Chinese pharmaceutical industry shares above feature for some aspects, but 
also has unique aspects. This report will see what is the true feature of China’s 
pharmaceutical firms. As above already mentioned, nature of demand for 
pharmaceuticals are subject to institutions such as health insurance and regulations such 
as price setting policy.  We will take a look at characteristics of demand and 
institutions in Part I, and will see firm’s behavior on pricing and innovation in Part II. 
 
3.  How to provide “Affordable, Safe, Sufficient and Sustainable” Drug in China? 
Since the Reform and Open Door Policy started in 1978, 30 years are passed. Target of 
policy and reform in China are moved from promoting efficiency by reforming industry 
to redistributing for equality recently. Medical care system reform invites social 
attentions, and its reform plan is currently discussed. Particularly, reform on hospital’s 
management is focus of this discussion. These discussions will substantially affect 
pharmaceutical industry, as hospital and pharmaceutical industry is strongly 
inter-connected. Furthermore, as we will see later, unusual demand feature of drugs in 
China, “Feeding Hospitals with Drugs” type demand, we called here, generates several 
problems in the pharmaceutical industry. The current controversies over the medical 
reform mainly argue on how to resolve this unusual type of demand. 
This research focuses on pharmaceutical industry. Our target is to explore the 
way to achieve “affordable, safe, sufficient and sustainable” supply system of 
pharmaceuticals. Theses targets are interconnected and have trade offs between 
themselves: Reform in medical care system will substantially change nature of demand 
of drugs: for example, share the health insurance will have in drug market, or their 
pricing mechanism. On the other hand, government requires the industry to upgrade 
their innovation capacity.  
Affordable price for the general public is necessary. However, if price of drug is 
set too low, they cannot afford to invest in innovation, or research and development that 
facilitate sufficient variety and good quality of drugs. On the same time, too low price of 
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drug will induce a problem in safety, as a certain amount of cost is necessary to secure a 
certain quality or safety of drug. As we will see later, price reduction by the government, 
not by price declines through market competition, will induce a halt of production of 
necessary, good and cheap drugs. Price setting mechanisms seriously affect 
sustainability and sufficiency in volume of pharmaceutical supply.  
 
4.  Summary of the report  
Chapter 1 shows demand nature and institutions, an environment of the pharmaceuticals 
in China. Here, we can see that (1) fiscal expenditure among medical expenditure is 
small in China, compared with other agents, individuals and social agents, as well as the 
other country. (2) Hospital deeply relies on the drug price margins. This creates 
“Feeding Hospitals with Drug” phenomena in China.  
 
Chapter 2 refers to the current price setting mechanisms in China. The current price 
setting mechanism in operation has following principles: 1) the State Development and 
Reform Committee (SDRC) has set a price cap on the retail price of drugs in the 
medical drug catalogues. 2) The price margin rule between forms of drug. The SDRC 
also set a price ratio among forms of drug, using a normal tablet as a reference. 3) 
However, patented drugs are free to have the maximum retail price set, being 
independent of government price regulations. Furthermore, 4) central tendering system 
via auction is employed at provincial level on the supply. Here, in China, duplicated 
several price controlling systems are seen. 
 
Chapter 3 sees institutions related to patent protection, new drug protection and 
innovation promoting policy. Patent protection systems in China are now consistent 
with international customs. As for patent, here we can see precise features on drug 
patent in China. Here we can see following types of patent are dominant (1) chemical 
drug , (2) ant-tumor, and cardiovascular drug, (3) applicant is firm and innovator is 
research institutes/universities, (4) in natural products field, Chinese agents are 
dominant. Until 2002, new drug protection system was operated independent to patent, 
which has substantially affected patent protection. The government also provides 
Chinese pharmaceuticals with various innovation promoting policy.      
 
Chapter 4 first confirms by data that “Feeding Hospitals with Drugs” really appears in 
China. Then, analyzed this demand nature will generate (1) higher supply price at 
factory, and (2) smaller amount of drug supply in the society, and (3) high retail price of 
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drugs are due to lack of competition in hospitals, thus, increased competition among 
suppliers by auctions etc. cannot reduce retail price, not resolve “High drug price 
problem.” Furthermore, aggressive reduction of official price cap will reduce supply of 
drugs. If the medical reform can normalize “Feeding Hospital with Drugs” type demand, 
(1) drug supply will increase, (2) firms can secure a certain profit, but could be smaller 
than current situation. In order to achieve “Cheap retail drug price,” introduction of  
competition among hospitals must be considered. This is out of scope of this report. 
 
Chapter 5 refers to current innovation situation and systems in China. This chapter 
introduced that innovation capacity of current Chinese pharmaceuticals are limited. 
However, some firms already turned to chase improvement of innovation capacity. In 
along with medical reforms, drug price will decrease in the long run, and focus of 
competition will move on to quality and product differentiation. Thus, firms must take 
policy to improve innovation capacity to survive. 
 12
